The desiccant (one or two containers) in the bottle, used to keep the tablets dry, should not be swallowed.Pack sizes of 2, 5, 7, 10, 14, 20, 28, 30, 50, 84, 100 tablets or multi-packs containing 98 (2 packs of 49) tablets in blisters; or 30 and 90 tablets in bottles with desiccant containers. The absolute bioavailability is approximately 100%. Arcoxia is a brand name for etoricoxib. To purchase this item you must have a prescription from a doctor. If signs of hepatic insufficiency occur, or if persistently abnormal liver function tests (three times the upper limit of normal) are detected, etoricoxib should be discontinued.If during treatment, patients deteriorate in any of the organ system functions described above, appropriate measures should be taken and discontinuation of etoricoxib therapy should be considered.

For ankylosing spondylitis the recommended dose is 90 mg once a day. In patients with moderate hepatic dysfunction (Child-Pugh score 7-9), regardless of indication, the dose of 30 mg Clinical experience is limited particularly in patients with moderate hepatic dysfunction and caution is advised. In some patients with insufficient relief from symptoms, an increased dose of 60 mg once daily may increase efficacy. No dosage adjustment is necessary for elderly patients. Women who use etoricoxib must not breast feed (see sections 4.3 and 5.3).The use of etoricoxib, as with any drug substance known to inhibit COX-2, is not recommended in women attempting to conceive.Patients who experience dizziness, vertigo or somnolence while taking etoricoxib should refrain from driving or operating machinery.In clinical trials, etoricoxib was evaluated for safety in 9,295 individuals, including 6,757 patients with OA, RA, chronic low back pain or ankylosing spondylitis (approximately 600 patients with OA or RA were treated for one year or longer).In clinical studies, the undesirable effects profile was similar in patients with OA or RA treated with etoricoxib for one year or longer.In a clinical study for acute gouty arthritis, patients were treated with etoricoxib 120 mg once daily for eight days. Patients enrolled in the Programme had a wide range of cardiovascular and gastrointestinal risk factors at baseline. By reporting side effects, you can help provide more information on the safety of this medicine.Keep this medicine out of the sight and reach of children.Do not use this medicine after the expiry date which is stated on the carton. You can also report side effects directly via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.

In the 53- and 106-week toxicity study, gastrointestinal ulcers were also seen at exposures comparable to those seen in man at the therapeutic dose. The adverse experience profile in this study was generally similar to that reported in the combined OA, RA, and chronic low back pain studies.In a cardiovascular safety outcomes programme of pooled data from three active comparator controlled trials, 17, 412 patients with OA or RA were treated with etoricoxib (60 mg or 90 mg) for a mean duration of approximately 18 months. Recurring Item.

For information regarding a dose related response for etoricoxib see section 5.1. These principal metabolites either demonstrate no measurable activity or are only weakly active as COX-2 inhibitors. Safety and effectiveness of etoricoxib in paediatric patients have not been established (see section 4.2).In preclinical studies, etoricoxib has been demonstrated not to be genotoxic.